cisplatin / Generic mfg. - LARVOL DELTA

Nanotechnology-based approaches for head and neck cancer treatment. (PubMed, Biomed Pharmacother) - "In this review, we summarize the development of different DDS platforms encapsulating either cisplatin or small-molecule inhibitors, highlighting preclinical studies and clinical trials in HNSCC. A particular emphasis is placed on the distinction between passive and active targeting strategies, offering a comprehensive overview of how nanoparticle functionalization and tumor-selective delivery can further enhance therapeutic outcomes. This dual perspective underscores the translational opportunities of nanomedicine within the evolving landscape of HNSCC treatment."

Journal • Review • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Targeted Protein Degradation

Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms. (PubMed, Acta Biomater) - "NMIBC usually affects the mucosa and submucosa of the bladder tissue, requiring tumor resection, followed by intravesical administration of mitomycin-C. MIBC commonly affects the deeper layers of bladder, being associated with the origin of metastases, and it is recommended to perform a radical cystectomy followed by cisplatin-based neoadjuvant chemotherapy...Organoids, spheroids, and hydrogels are established drug screening tools. 3D models show strong potential for translation into clinical applications."

Journal • Preclinical • Review • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Celastrol synergizes with MEK1 inhibitor nedometinib to overcome resistance in bladder cancer via dual suppression of CDK1/CDC5L and feedback-activated Akt/STAT3. (PubMed, Biochem Pharmacol) - "Bladder cancer, particularly in its advanced and cisplatin-resistant forms, poses a significant clinical challenge due to limited therapeutic options...Our results indicate that CST dually inhibits CDK1 and CDC5L and synergizes with the MEK1 inhibitor by suppressing feedback-driven resistance pathways. These findings support the CST + NB combination as a novel multi-target therapeutic strategy with potent activity against bladder cancer and rectal adenocarcinoma."

Journal • Bladder Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Genito-urinary Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • CDK1 • PTEN • STAT3

Collision-induced ribosome degradation driven by ribosome competition and translational perturbations. (PubMed, Nat Commun) - "We further show that endogenous ribosomal subunit stoichiometry shifts toward a small-subunit-shortage state via ubiquitination upon perturbed translation triggered by the anti-cancer drug cisplatin and the growth phase transition. These findings reveal a mechanism by which ribosome dynamics generally affects ribosome stability, implicating ribosome dysfunction, heterogeneity, and stress-related translational disturbances in small subunit degradation."

Journal • Oncology • Targeted Protein Degradation

REVIVE: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: AstraZeneca

Biomarker • New P4 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Tumor-infiltrating lymphocyte therapy in lung cancer: A systematic review (ASH 2025) - "TILs were sourced from lung or metastatic sites, expanded ex vivo, and administered following lymphodepletion (primarily cyclophosphamide/fludarabine)...Median OS was 22.4 months in the TIL group, compared to 14.1 months with cisplatin (Ratto et al.) and 371.8 days in another TIL cohort (Chu et al.)... TIL therapy shows encouraging clinical activity and manageable toxicity in lung cancer, with improvements in survival, response rates, and quality of life. However, small sample sizes and study variability limit definitive conclusions. Larger, standardized trials are needed to confirm its long-term benefits."

IO biomarker • Review • Tumor-infiltrating lymphocyte • Febrile Neutropenia • Hypotension • Lung Cancer • Melanoma • Neutropenia • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • PD-L1

Isa-PACE in the treatment of functionally high-risk multiple myeloma: Intermediate results. (ASH 2025) - "In the absence of chimeric antigen receptor T-cell (CAR-T) therapy in Russia, the Isa-PACE (isatuximab + cisplatin, doxorubicin, cyclophosphamide, and etoposide) combination is considered a potential bridge therapy to auto-HSCT...All patients continue to receive maintenance therapy with isatuximab and lenalidomide, while maintaining MRD-negative status...Intermediate assessment of PET/CT imaging effectively reflected the response to treatment and identified the need for treatment intensification. Expanding the sample size will help to clarify the prognostic significance of this approach and aid in stratifying patients with NDMM."

Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Human Papillomavirus Infection • Infectious Disease • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia

Outcomes of infusional chemotherapy regimens in multiple myeloma: A retrospective review at a single center from 2018 to 2025 (ASH 2025) - "Despite emergence of novel agents, the use of traditional multi-agent infusional regimens such as DCEP (dexamethasone, cyclophosphamide, etoposide, cisplatin) and V(T)D-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) remain critical in select clinical scenarios. These regimens continue to be valuable in providing rapid cytoreduction or as a bridge to definitive therapy. Larger sample sizes are required in order to perform statistical analysis on subgroups to better characterize differences in therapy with respect to progression free survival, overall response rate, and time to response."

Retrospective data • Review • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

High transplant conversion rates with gemcitabine, dexamethasone and carboplatin (GDP)-based therapy in Relapsed/Refractory lymphoma: A real-world experience (ASH 2025) - "G-CSF and Plerixafor-mobilized peripheral blood stem cell were used in all patients...Eligible patients received agents like Rituximab, Brentuximab, and Nivolumab with additional cost per cycle...The regimen's daycare feasibility and reduced hospitalization needs offer significant quality-of-life and economic advantages. Substituting Carboplatin for Cisplatin further enhances administration convenience."

Clinical • Real-world • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Transplantation

Experience with prolgolimab in the treatment of patients with relapsed and refractory classical Hodgkin lymphoma (ASH 2025) - "Objective: To evaluate the efficacy and safety of prolgolimab both as monotherapy and in combination with DHAP chemotherapy (dexamethasone, cytarabine, cisplatin), as well as to assess the feasibility of peripheral blood stem cell (PBSC) collection followed by auto-HSCT in patients with r/r cHL...Disease progression was noted in 6 patients, who were subsequently switched to bendamustine-based chemotherapy regimens. PBSC collection was successfully performed in 15 patients after chemomobilization with etoposide (375 mg/m²/day on days 1–2)... The combination of prolgolimab with DHAP chemotherapy is highly effective and safe, with no negative impact on PBSC collection. Achieving tumor response prior to auto-HSCT and the use of prolgolimab as consolidation therapy can lead to durable remissions without additional toxicity in patients with r/r cHL."

Clinical • Bone Marrow Transplantation • Cardiovascular • Classical Hodgkin Lymphoma • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Pulmonary Embolism • Respiratory Diseases • CD34 • PD-L2

Real-world outcomes of Mantle Cell Lymphoma in Colombia: A multicenter cohort study (ASH 2025) - "The most common induction regimens were cytarabine-based, including Rituximab - cyclophosphamide - doxorrubicin - vincristin - prednisolone (R-CHOP)/ Rituximab - dexamethasone - citarabine - cisplatin (R-DHAP) (LYMA) (46.2%, n = 37) followed by the Nordic regimen (12%, n = 10) and Bendamustine-Rituximab (BR)(10.0%, n = 8). Other treatment regimens were R-CHOP/R-miniCHOP (10.0%, n = 8), and rituximab - bendamustine - cytarabine (R-BAC) (8.8%, n = 7)...Of 39 receiving second-line therapy, 31 (44%) were treated with BTK inhibitor ibrutinib, which remains approved only for relapsed/refractory disease in Colombia... Our 5-year overall survival (OS) rate of 66.2% exceeded the 57.1% reported in a broader Latin American cohort (Pavlovsky et al., 2022), suggesting potential regional differences in outcomes. Despite the established survival benefit of autologous stem cell transplantation (ASCT), over one-third of eligible patients did not undergo transplant, highlighting ongoing..."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • MYC • SOX11 • TP53

Establishment of a prognostic model for diffuse large B-cell lymphoma based on mitochondrial energy metabolism-related genes (ASH 2025) - "Drug sensitivity prediction further revealed that high-risk patients may respond better to cisplatin and oxaliplatin but show reduced sensitivity to venetoclax. In summary, this study established a novel MMRG-based prognostic model that enables precise risk stratification and reveals key links between mitochondrial metabolism and the immune landscape in DLBCL. These findings provide valuable insights for individualized prognosis evaluation and the development of metabolism-immune targeted therapies."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • ACSL5 • ADH1A • ASXL1 • CPT1A • DOT1L • MCL1 • PLK1

Molecular pathology of testicular germ cell tumours: an update for practicing pathologists. (PubMed, Histopathology) - "Alterations associated with the formation of a somatic-type malignancy and/or the development of cisplatin resistance include TP53 mutations or MDM2 gene amplifications as well as epigenetic alterations...Additionally, we will provide guidance on how to examine a testicular tumour specimen histopathologically to reach an accurate diagnosis. Finally, we will outline the importance of the content of a histopathological report for the urologists and oncologists."

Biomarker • Journal • Review • Embryonal Tumor • Germ Cell Tumors • Oncology • Testicular Cancer • Testicular Seminoma • AFP • BRAF • DMRT1 • KIT • KRAS • MDM2 • TP53

Four new dammarane nortriterpenoids isolated from mastic (Pistacia lentiscus L.) and their anti-inflammatory and cytotoxic activities. (PubMed, Nat Prod Res) - "Compounds 5-8 showed certain inhibitory NO production in LPS-induced RAW264.7 cells with IC50 values of 24.84-37.15 μM (positive control dexamethasone, 11.27 ± 2.25 μM). Compound 7 significantly inhibited the growth of SW480 cells, with an IC50 value of 30.76 ± 2.75 μM, comparable to that of the positive control cisplatin (25.91 ± 1.44 μM). Additionally, the effects of all the compounds on HCT116 cells were not significant."

Journal

Probing drug pharmacokinetics using neutron scattering techniques. (PubMed, Phys Chem Chem Phys) - "Two drugs were studied, a dinuclear Pd-complex and the clinical agent cisplatin...Opposite effects were detected for the Pt- and Pd-agents regarding the protein's local and internal dynamics. The influence of the Pd-compound at the nanosecond scale is particularly intriguing, as it reduced the observed backbone dynamics below 290 K. This enhanced knowledge on the drug's pharmacokinetics is expected to contribute to the design of improved anticancer agents (with lower toxicity and increased bioavailability at the target)."

Journal • PK/PD data • Oncology

Immunotherapy for urological cancers in 2025 (PubMed, Magy Onkol) - "By 2025, immunotherapy has become the therapeutic basis for UC and RCC, both in metastatic and curative treatments. In PCa and TGCT, immunotherapy options remain in the experimental phase, but research is ongoing with new combinations and biomarker-driven strategies."

IO biomarker • Journal • Review • Genito-urinary Cancer • Germ Cell Tumors • Microsatellite Instability • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Testicular Cancer • Urethral Cancer • Urothelial Cancer • MSI

Trilaciclib for the prevention of chemotherapy-induced myelosuppression: A systematic review and meta-analysis (ASH 2025) - "Chemotherapy regimens were heterogeneous and included etoposide-platinum (E/P) (either cisplatin or carboplatin) (n=5), gemcitabine/carboplatin (GCb) (n=2), topotecan (n=2), FOLFOXIRI (n=1), and Carboplatin/Paclitaxel/Tislelizumab (n=1)...It also showed a positive impact on progression-free and overall survival, without compromising chemotherapy effectiveness or increasing toxicity. These findings highlight Trilaciclib's potential as a valuable adjunct to chemotherapy in appropriately selected patients."

Retrospective data • Review • Breast Cancer • Colorectal Cancer • Febrile Neutropenia • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer

Haematological toxicities with targeted drugs in tumors: A systematic review and network meta-analysis of randomized controlled trials (ASH 2025) - "1 patient treated with sorafenib plus chemotherapy was reported to have died as a result of pancytopenia and 1 patient treated with chemotherapy (gemcitabine plus cisplatin) died due to anemia. Our study confirmed that chemotherapy with or without a placebo, one targeted drug with chemotherapy was associated with more severe hematologic toxicities compared with the use of one targeted drug, tepotinib plus gefitinib, tivantinib plus erlotinib. In the targeted drug monotherapy category, for the primary outcome, we found that alectinib and gefitinib had a higher risk of all-grade (grade 1-5) and severe-grade (grade 3-5) anemia, respectively...Ganitumab plus chemotherapy had the highest risk of grade 1-5 anemia and thrombocytopenia. Afatinib plus chemotherapy had the highest risk of grade 3-5 anemia and thrombocytopenia. Ramucirumab plus chemotherapy had the highest risk of grade 1-5 and 3-5 neutropenia. Veliparib plus chemotherapy had the highest risk of grade 1-5 and 3-5..."

Retrospective data • Review • Febrile Neutropenia • Leukopenia • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDPM) in Relapsed/Refractory diffuse large B-cell lymphoma: A multicenter, single-arm study (ASH 2025) - "The combination of Lipo-MIT with R-GDP demonstrated encouraging efficacy and a manageable safetyprofile in patients with R/R DLBCL. Further studies with continued follow-up are warranted to assesssurvival outcomes."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study (ASH 2025) - "Recently, forthe first time, a significant OS benefit was demonstrated for the combination of brentuximab vedotin (BV)and CHP (cyclophosphamide, doxorubicin, prednisone) compared to CHOP (cyclophosphamide,doxorubicin, vincristine, prednisone) in the first-line treatment of patients with anaplastic large celllymphoma (ALCL)...In Hodgkin lymphoma, the addition of BVto DHAP (dexamethasone, high-dose cytarabine, cisplatin) has shown promising efficacy as a salvageregimen in a phase II trial...No new cases of peripheral neuropathy weredocumented.In conclusion, BV-DHAP was particularly effective as a salvage regimen in this high-risk cohort of R/RCD30-positive T-cell non-Hodgkin lymphoma, with manageable toxicity. Further studies are warranted toestablish its superiority over BV monotherapy in this setting."

Retrospective data • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results (ASH 2025) - P2 | "This study aims toevaluate the efficacy and safety of daratumumab-carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation (ASCT) inthis population (NCT06140966). In this multicenter phase 2 trial , transplant-eligible NDMM patients (aged 18-70 years; ECOG ≤2before induction therapy) with UHiR (defined as "double-hit" MM (≥2 high-risk cytogenetic abnormalities[HRCAs]: t(4; 14), t(14; 16), t(14; 20), 1q+, del(17p), TP53 mutation), extramedullary disease (EMD), orprimary plasma cell leukemia (pPCL)) received 1 cycle of pretrial induction therapy with regimens such asVRD, VCD, or KRD, followed by induction with 2-4 cycles of Dara-KRd-PACE (Daratumumab 16 mg/kg days1,8; Carfilzomib 20/27 mg/m² days 1,2,8,9; Lenalidomide 25 mg days 1-7; Dexamethasone 40 mg days1,8,15,22; Cisplatin 10 mg/m² days 1-4; Epirubicin 10 mg/m² days 1-4; Cyclophosphamide 400 mg/m² days1-4; Etoposide 40 mg/m² days..."

Clinical • Infectious Disease • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia • Thrombosis • Transplantation • CD34 • TP53

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma (ASH 2025) - P2 | "Moreover,severe short- and long-term side effects remain major concerns.Recent studies suggest high response rates of up to 95% and unprecedented progression-free survival(PFS) with anti-programmed cell death protein 1 (PD-1)-based salvage regimens such as pembrolizumab,gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD)...Initiatedin March 2024 at four German centers, the trial has enrolled 23 patients to date.Patients receive an initial cycle of pembrolizumab followed by two cycles of P-ICE (pembrolizumab,ifosfamide, carboplatin, etoposide). After PET restaging, complete responders continue with two morecycles of P-ICE, while patients failing to achieve a complete response switch to two cycles of P-DHAP(pembrolizumab, dexamethasone, high-dose cytarabine, cisplatin)...The interim analysis of the Pembro-CORE trial demonstrates promising early results for a PET-adapted,HD-CT-free treatment strategy in first-relapsed cHL. A high CMR of 93.3% was observed among..."

P2 data • Acute Kidney Injury • Classical Hodgkin Lymphoma • Dermatitis • Dermatology • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Nephrology • Neutropenia • Renal Disease • Respiratory Diseases

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis (ASH 2025) - "The eBEACOPDac regimen, which replaces procarbazine with dacarbazine, isfavoured in some countries due to reduced gonadal and hematologic toxicity, with similar survival rates(Santarsieri, Lancet Oncol 2025)...Most patientsreceived conventional combination 2L chemotherapy (chemo, n=55; 76%), with gemcitibine,dexamethasone and cisplatin (GDP) most frequently used (n=48; 67%). 17 patients (24%) received 2Ltargeted agents: pembro-GVD (n=8), BV-DHAC (n=5), BV-nivo (n=2), pembro-ICE (n=1) and BrentuximabVedotin (BV) monotherapy (n=1)... For R/R HL after 1L eBEACOPDac, patients treated with 2L chemo have inferior outcomes compared topatients who relapse after ABVD. This informs our discussions with patients who relapse after 1LeBEACOPDac when consenting to 2L treatment. The use of 2L targeted agents was associated withsubstantially better outcomes, with a 47% difference in 2-yr PFS, which is unlikely to be attributable todifferences in baseline characteristics alone."

Adverse events • Clinical • Real-world • Real-world evidence • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Quizartinib enhances conditioning for hematopoietic stem cell transplantation via transcriptional suppression of DNA repair pathways (ASH 2025) - "To assess HSC transplantation efficacy, mice were conditioned with 700 or1000 Rads of TBI, transplanted with 2 million CD45.1 bone marrow (BM) cells, and monitored for donorcell engraftment for 4 months. Quizartinib synergized with DNA damaging chemotherapeutic agents (cyclophosphamide,carboplatin, cisplatin, temozolomide, and mitoxantrone) to deplete HSPC populations. Quizartinib sensitizes HSPCs to DNA-damaging therapies via downregulation of DNA repairgenes and impaired resolution of DNA damage, resulting in enhanced HSPC depletion. This quizartinib-driven sensitization demonstrated improved engraftment after HSCT in murine models. These resultsprovide a rationale for incorporating quizartinib into reduced-intensity, myeloablative conditioningregimens to improve transplant outcomes while minimizing non-hematopoietic toxicity."

Bone Marrow Transplantation • Transplantation • BRCA1 • BRCA2 • CD34 • FLT3 • NBN • PTPRC • RAD51